Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies

Yuanyuan Feng; Lihong Zhou; Xiaoting Sun; Qi Li

doi:10.18632/oncotarget.14723

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies

Yuanyuan Feng, Lihong Zhou, Xiaoting Sun and Qi Li _

PDF | HTML | How to cite

Oncotarget. 2017; 8:20452-20461. https://doi.org/10.18632/oncotarget.14723

Metrics: PDF 1928 views | HTML 2982 views | ?

Abstract

Yuanyuan Feng1,*, Lihong Zhou1,*, Xiaoting Sun1 and Qi Li1

1 Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

* These authors have contributed in equal measure as the first author

Correspondence to:

Qi Li, email:

Keywords: HIPK2; cancer; p53; apoptosis; angiogenesis

Received: September 02, 2016 Accepted: January 04, 2017 Published: January 18, 2017

Abstract

The HIPK2 (serine/threonine homeodomain-interacting protein kinase 2) is a “caretaker” gene, its inactivation increases tumorigenicity while its activation inhibits tumor growth. This report reviews the anti-tumorigenic mechanisms of HIPK2, which include promotion of apoptosis, inhibition of angiogenesis in hypoxia, prevention of tumor invasion/metastasis and attenuation of multidrug resistance in cancer. Additionally, we summarize conditions or factors that may increase HIPK2 activity.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14723

Publication Alerts

Reviews:

Homeodomain-interacting protein kinase 2 (HIPK2): a promising target for anti-cancer therapies

Abstract